MMR Announces 13 Health Information Technology Patents -- Portfolio
Includes Claims for Sharing of Medical Records With Multiple
Providers
LOS ANGELES, CA--(Marketwired - Jun 16, 2014) - MMRGlobal, Inc.
(OTCQB: MMRF), through its wholly owned subsidiary
MyMedicalRecords, Inc. (collectively, "MMR"), today announced that
it will receive U.S. Patent No. 8,768,725 (the '725 Patent) from
the United States Patent and Trademark Office. The '725 patent
includes claims directed to the sharing of records with a second
healthcare provider to better manage and facilitate second
opinions. MMR will now have a total of 36 patents including 13
domestic health information technology (HIT) patents, seven foreign
HIT patents, and 16 biotech patents. Based on licenses pertaining
to its U.S. patent portfolio, MMR already has agreements worth more
than $40,000,000 as set forth in the agreements. In addition,
ongoing royalties from sales and licensing including recurring
revenues from retail and laboratory services could easily double
that amount. MMR also projects revenue growth from domestic
and international retail pharmacies, grocery retail, employee
benefit programs, Etailers, affiliate marketers and other eHealth
providers including 4medica and a recently signed Patent Agreement
with Cerner Corp. For example, MMR expects online Etailer
distribution to reach more than 40 million households each month
and 12,000 in-store U.S. pharmacies this year. MMR also licensed
distribution in European-based pharmacy retailers with more than
1,000 stores.
MyMedicalRecords, Inc. is a practicing entity and a leading
provider of secure and easy-to-use Personal Health Records (PHRs)
through its MyMedicalRecords PHR, and MMRPro and MMRProPlus
document management and imaging systems for healthcare
professionals. After issuance of Patent No. 8,768,725, MMR's
patent portfolio will include 13 U.S. patents, including U.S.
Patent Nos. 8,121,855; 8,117,045; 8,117,646; 8,301,466; 8,321,240;
8,352,287; 8,352,288; 8,498,883; 8,626,532, 8,645,161; 8,725,537,
and including a NOA for Serial No. 13/082,896. The patents
collectively include over 275 issued claims and there are
additional pending applications and continuation
applications. The '725 patent is scheduled to issue on July 1,
2014. MMR also has similar HIT patents and pending applications in
11 other countries or regional authorities of commercial interest
including Australia, Canada, Singapore, New Zealand, Mexico, Hong
Kong, China, Japan, South Korea, Israel, and Europe.
The Company has three separate patent portfolios currently
comprising the 36 patents and additional pending applications and
continuation applications. The first is directed at Electronic
Medical Records with a primary focus on Personal Health Records;
another portfolio centers around the use of PHRs in connection with
Clinical Trials, which MMR plans on licensing through existing
relationships with Big Pharma and the biotech community. The
third portfolio includes MMRGlobal's legacy biotech patents from
the Company's FavId™ vaccine trials and clinical research related
to cancer-fighting anti-CD20 monoclonal antibodies.
Last month the Company also announced a Notice of Allowance for
MMR's first Clinical Trials patent which includes 18 claims
directed to methods and systems that provide for self-reporting
being used to create Electronic Health Records for purposes
including clinical trials. At the same time, MMR announced the
issuance of U.S. Patent No. 8,725,537, entitled "Method and System
for Providing Online Records," which expands MMR's health IT
patents with claims directed toward storing, managing and sharing
legal records. This patent broadens MMR's intellectual
property beyond PHRs and other forms of Electronic Medical Records
into the legal field. The '537 patent is particularly relevant to
the management of wills and powers of attorney and advanced
directives which can be included as part of an individual's
Personal Health Record account.
Although MMR's primary business is as a provider and licensor of
health IT products and services, the Company also has a portfolio
of biotech patents. These pertain to cancer-fighting anti-CD20
monoclonal antibodies under the title, "Antibodies and Methods For
Making and Using Them," issued in the U.S., Mexico, Australia and
South Korea, with additional patents pending in the U.S.,
Australia, Brazil, Canada, China, Hong Kong, India, Europe, Japan
and Korea, and additional patents pertaining to its B-cell idiotype
vaccine worldwide.
About MMRGlobal MMRGlobal, Inc., through its wholly-owned
operating subsidiary, MyMedicalRecords, Inc., provides secure and
easy-to-use online Personal Health Records ("PHRs") and electronic
safe deposit box storage solutions, serving consumers, healthcare
professionals, employers, insurance companies, financial
institutions, retail pharmacies, and professional organizations and
affinity groups. The MyMedicalRecords PHR enables individuals and
families to access their medical records and other important
documents, such as birth certificates, passports, insurance
policies and wills, anytime from anywhere using the Internet.
MyMedicalRecords is built on proprietary, patented technologies to
allow documents, images and voicemail messages to be transmitted
and stored in the system using a variety of methods, including fax,
phone, or file upload without relying on any specific electronic
medical record platform to populate a user's account. MMR's
professional offering, MMRPro, is designed to give physicians'
offices an easy and cost-effective solution to digitizing
paper-based medical records and sharing them with patients through
an integrated patient portal. Through its merger with Favrille,
Inc. in January 2009, MMR acquired intellectual property biotech
assets that include anti-CD20 antibodies and data and samples from
its FavId™/Specifid™ vaccine clinical trials for the treatment of
B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc.
visit www.mmrglobal.com. View demos and video tutorials of MMR's
products and services at www.mmrtheater.com. Follow us at
Facebook.com/MMRGlobal and Twitter.com/mmrglobal.
Forward-Looking Statements All statements in this press release
that are not strictly historical in nature, including, without
limitation, intellectual property licenses, intellectual
property enforcement actions, infringement claims or litigation,
and future performance, management's expectations, beliefs,
intentions, estimates or projections, constitute "forward-looking
statements." Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause MMR's
actual results to be materially different from historical results
or from any results expressed or implied by such forward-looking
statements. Some can be identified by the use of words (and their
derivations) such as "need," "possibility," "potential," "intend,"
"offer," "development," "if," "negotiate," "when," "begun,"
"believe," "achieve," "will," "estimate," "expect," "maintain,"
"plan," and "continue," or the negative of these words. Actual
outcomes and results of operations and the timing of selected
events may differ materially from the results predicted, and any
reported results should not be considered as an indication of
future performance. Such statements are necessarily based on
assumptions and estimates and are subject to various risks and
uncertainties, including those relating to the possible invalidity
of the underlying assumptions and estimates and possible changes or
developments in economic, business, industry, market, legal and
regulatory circumstances and conditions and actions taken or
omitted to be taken by third parties, including customers,
suppliers, business partners, potential licensees, competitors and
legislative, judicial and other governmental authorities and
officials. Factors that could cause or contribute to such
differences include, but are not limited to: unexpected outcomes
with respect to intellectual property enforcement actions, claims
of intellectual property infringement and general intellectual
property litigation; our ability to maintain, develop, license,
monetize and protect our patent portfolio for both MMR's health IT
and biotechnology intellectual property assets in the U.S. and
internationally; the timing of milestone payments in connection
with licensing our intellectual property; our ability to establish
and maintain strategic relationships; changes in our relationships
with our licensees; the risk MMR's products are not adopted or
viewed favorably by the healthcare community and consumer retail
market; business prospects, results of operations or financial
condition; risks related to the current uncertainty and instability
in financial and lending markets, including global economic
uncertainties; the timing and volume of sales and installations;
the length of sales cycles and the installation process; the
market's acceptance of new product and service introductions;
competitive product offerings and promotions; changes in government
laws and regulations including the 2009 HITECH Act and changes in
Meaningful Use and the 2010 Affordable Care Act; future changes in
tax legislation and initiatives in the healthcare industry;
undetected errors in our products; the possibility of interruption
at our data centers; risks related to third party vendors; risks
related to obtaining and integrating third-party licensed
technology; risks related to a security breach by third parties;
risks associated with recruitment and retention of key personnel;
other litigation matters; uncertainties associated with doing
business internationally across borders and territories; and
additional risks discussed in MMR's filings with the Securities and
Exchange Commission. MMR is providing this information as of
the date of this release and, except as required by applicable law,
does not undertake any obligation to update any forward-looking
statements contained in this release as a result of new
information, future events or otherwise.
CONTACT: Michael Selsman Public Communications Co.
ms@publiccommunications.biz (310)
922-7033